Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

References

• ThriftAPEl-SeragHBKanwalFGlobal epidemiology and burden of HCV infection and HCV-related diseaseNat Rev Gastroenterol Hepatol201714212213227924080
   PubMed Web of Science ®Google Scholar
• PetruzzielloAMariglianoSLoquercioGCozzolinoACacciapuotiCGlobal epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypesWorld J Gastroenterol201622347824784027678366
   PubMed Web of Science ®Google Scholar
• LauerGMWalkerBDHepatitis C virus infectionN Engl J Med20013451415211439948
   PubMed Web of Science ®Google Scholar
• World Health OrganizationGuidelines for the Screening, Care, and Treatment of Persons with Chronic Hepatitis C Infection: Updated VersionGenevaWHO2016
   Google Scholar
• SmithDBBukhJKuikenCExpanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resourceHepatology201459131832724115039
   PubMed Web of Science ®Google Scholar
• MessinaJPHumphreysIFlaxmanAGlobal distribution and prevalence of hepatitis C virus genotypesHepatology2015611778725069599
   PubMed Web of Science ®Google Scholar
• RaoHWeiLLopez-TalaveraJCDistribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infectionJ Gastroenterol Hepatol201429354555324090188
   PubMed Web of Science ®Google Scholar
• NiederauCHüppeDZehnterEChronic hepatitis C: treat or wait? Medical decision making in clinical practiceWorld J Gastroenterol201218121339134722493547
   PubMed Web of Science ®Google Scholar
• LawitzELalezariJPHassaneinTSofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialLancet Infect Dis201313540140823499158
   PubMed Web of Science ®Google Scholar
• OgataNAlterHJMillerRHPurcellRHNucleotide sequence and mutation rate of the H strain of hepatitis C virusProc Natl Acad Sci U S A1991888339233961849654
   PubMed Web of Science ®Google Scholar
• CoppolaNMinichiniCStaraceMSagnelliCSagnelliEClinical impact of the hepatitis C virus mutations in the era of directly acting antiviralsJ Med Virol201688101659167126991255
   PubMed Web of Science ®Google Scholar
• LontokEHarringtonPHoweAHepatitis C virus drug resistance-associated substitutions: state of the art summaryHepatology20156251623163226095927
   PubMed Web of Science ®Google Scholar
• NittaSAsahinaYMatsudaMEffects of resistance-associated NS5A mutations in hepatitis C virus on viral production and susceptibility to antiviral reagentsSci Rep201663465227703205
   PubMed Web of Science ®Google Scholar
• IioEShimadaNAbeHEfficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1J Gastroenterol20175219410327236547
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the LiverEASL recommendations on treatment of hepatitis C 2016J Hepatol201766115319427667367
   PubMed Web of Science ®Google Scholar
• TamuraKPetersonDPetersonNStecherGNeiMKumarSMEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methodsMol Biol Evol201128102731273921546353
   PubMed Web of Science ®Google Scholar
• DonlinMJSzetoBGoharaDWAuroraRTavisJEGenome-wide networks of amino acid covariances are common among virusesJ Virol20128663050306322238298
   PubMed Web of Science ®Google Scholar
• AuroraRDonlinMJCannonNATavisJEGenome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humansJ Clin Invest2009119122523619104147
   PubMed Web of Science ®Google Scholar
• ClineMSSmootMCeramiEIntegration of biological networks and gene expression data using CytoscapeNat Protoc20072102366238217947979
   PubMed Web of Science ®Google Scholar
• IzumiNHayashiNKumadaHOnce-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studiesJ Gastroenterol201449594195324626851
   PubMed Web of Science ®Google Scholar
• LenzOVerbinnenTFeveryBVirology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIB/III studiesJ Hepatol20156251008101425445400
   PubMed Web of Science ®Google Scholar
• BartelsDJZhouYZhangEZNatural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naïve subjectsJ Infect Dis2008198680080718637752
   PubMed Web of Science ®Google Scholar
• GaoMAntiviral activity and resistance of HCV NS5A replication complex inhibitorsCurr Opin Virol20133551452023896281
   PubMed Web of Science ®Google Scholar
• ChenZWLiHRenHHuPGlobal prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome dataSci Rep201662031026842909
   PubMed Web of Science ®Google Scholar
• SarrazinCThe importance of resistance to direct antiviral drugs in HCV infection in clinical practiceJ Hepatol201664248650426409317
   PubMed Web of Science ®Google Scholar
• NakamotoSKandaTWuSShirasawaHYokosukaOHepatitis C virus NS5A inhibitors and drug resistance mutationsWorld J Gastroenterol201420112902291224659881
   PubMed Web of Science ®Google Scholar
• HézodeCHirschfieldGMGhesquiereWDaclatasvir plus peginterferon alfa and ribavirin for treatment-naïve chronic hepatitis C genotype 1 or 4 infection: a randomised studyGut201564694895625080450
   PubMed Web of Science ®Google Scholar
• BartelsDJSullivanJCZhangEZHepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naïve patients prior to treatmentJ Virol20138731544155323152524
   PubMed Web of Science ®Google Scholar
• FridellRAQiuDWangCValeraLGaoMResistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon systemAntimicrob Agents Chemother20105493641365020585111
   PubMed Web of Science ®Google Scholar
• BagaglioSAndolinaAMerliMUberti-FoppaCMorsicaGFrequency of natural resistance within NS5A replication complex domain in hepatitis C genotypes 1a, 1b: possible implication of subtype-specific resistance selection in multiple direct acting antivirals drugs combination treatmentViruses2016849127023593
   PubMed Web of Science ®Google Scholar
• SchinaziRHalfonPMarcellinPAsselahTHCV direct-acting antiviral agents: the best interferon-free combinationsLiver Int201434Suppl 16978
   PubMed Web of Science ®Google Scholar
• DonaldsonEFHarringtonPRO’RearJJNaegerLKClinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvirHepatology2015611566525123381
   PubMed Web of Science ®Google Scholar
• HangJQYangYHarrisSFSlow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virusJ Biol Chem200928423155171552919246450
   PubMed Web of Science ®Google Scholar
• KrishnanPTripathiRSchnellGResistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvirAntimicrob Agents Chemother20155995445545426100711
   PubMed Web of Science ®Google Scholar
• LiZZhangYLiuYNaturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naïve HCV genotype 1b-infected patients in ChinaMedicine (Baltimore)20179619e683028489763
   PubMed Web of Science ®Google Scholar